Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Beta-hydroxybutyrate suppresses hepatic production of the ghrelin receptor antagonist, LEAP2

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Diagnosis of Thrombotic Thrombocytopenic Purpura by ADAMTS13 Activity Quantification

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

AIMS: To investigate the effect of adding the short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes.

MATERIALS AND METHODS: In a randomized, double-blind, parallel-group trial, 108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy with a body mass index >22.0 kg/m2 and glycated haemoglobin concentration of 59 to 88 mmol/mol (7.5%-10.0%) were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta®) or placebo three times daily over 26 weeks as add-on treatment to existing insulin therapy. Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population. The primary results of this study, the MAG1C (Meal-time Administration of exenatide for Glycaemic control in type 1 diabetes Cases) trial, were previously reported.

RESULTS: Exenatide changed total fat mass by -2.6 kg (95% confidence interval [CI] -3.6; -1.6; P < 0.0001) and lean body mass by -1.1 kg (95% CI -1.9; -0.4; P = 0.01) compared with placebo, as assessed by dual-energy X-ray absorptiometry. Fat mass reductions were similar for central and peripheral fat mass. Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-α; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (DNA oxidation marker).

CONCLUSIONS: Exenatide added to insulin therapy in type 1 diabetes for 26 weeks resulted in body weight loss primarily from fat mass reduction, but had no effect on biomarkers of cardiovascular disease risk.

TidsskriftDiabetes, Obesity and Metabolism
Udgave nummer9
Sider (fra-til)1639-1647
Antal sider9
StatusUdgivet - sep. 2020

Bibliografisk note

© 2020 John Wiley & Sons Ltd.

ID: 60074088